Related Experiment Video

Updated: Jun 25, 2026

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II

Lan-Feng Dong1, Ruth Freeman, Ji Liu

  • 1Apoptosis Research Group and Genomic Research Centre, School of Medical Science, Griffith University, Southport, Queensland, Australia. l.dong@griffith.edu.au

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 19, 2009
PubMed
Abstract

Insights

Vitamin E analogues like alpha-tocopheryl succinate (alpha-TOS) show anticancer potential. This study reveals mitochondrial complex II (CII) as a key cellular target for alpha-TOS, demonstrating its effectiveness against tumors with functional CII.

Area of Science:

  • Biochemistry
  • Oncology
  • Mitochondrial Biology

Background:

  • Vitamin E analogues, such as alpha-tocopheryl succinate (alpha-TOS), are recognized for their potent anticancer properties.
  • Understanding the precise cellular mechanisms and targets of these novel anticancer agents is crucial for their therapeutic development.

Purpose of the Study:

  • To identify the specific cellular target of vitamin E analogues, exemplified by alpha-TOS, in suppressing tumor growth in vivo.
  • To investigate the role of mitochondrial complex II (CII) as a potential target for alpha-TOS-mediated anticancer effects.

Main Methods:

  • Utilized Chinese hamster lung fibroblasts engineered with varying functional states of mitochondrial complex II (CII).
  • Transformed cells with H-Ras and established xenografts in immunocompromised mice to study tumor response.
  • Assessed the effects of alpha-TOS on cellular reactive oxygen species (ROS) generation, apoptosis, and tumor growth suppression.

Main Results:

  • alpha-TOS induced reactive oxygen species (ROS) generation and apoptosis in cells with functional or reconstituted CII.
  • Tumors derived from CII-functional and CII-reconstituted cells exhibited significant growth suppression and apoptosis upon alpha-TOS treatment.
  • alpha-TOS failed to inhibit tumors originating from CII-dysfunctional cells, highlighting the critical role of CII.

Conclusions:

  • Mitochondrial complex II (CII) is identified as a novel and plausible cellular target for anticancer drugs based on vitamin E analogues.
  • This finding supports the potential of vitamin E analogues as a new class of anticancer therapeutics.
  • The study advocates for the clinical evaluation of vitamin E analogues targeting mitochondrial CII in cancer treatment.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis08:15

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Published on: February 3, 2022

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...